Mixed results from a study focused on lower back pain left analysts wanting as well as confused about Vertex's plans to forge ...
The company is planning a “broad Phase 3 program” for two anticoagulants after they outperformed marketed medicines in a pair ...
Novo shares lost nearly a fifth of their value after an experimental combination treatment called cagrisema fell short of the ...
The FDA’s decision will close a lucrative market opportunity for compounding pharmacies, although the agency will give a ...
An startup formed by KdT Ventures intends to test the drug, which was once licensed to Merck and evaluated in multiple ...
The clearance of Tryngolza gives Ionis its first wholly-owned, marketed medicine. Elsewhere, Robert Temple became the latest ...
While the pharma is still developing a MorphoSys drug acquired in its $2.9 billion deal for the biotech, it is closing down sites in the U.S. and Germany.
Dec. 21, 2024 – Dec. 31, 2024 • New York, NY, USA, New York ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback